I doubt that.
It doesn't matter what the cash burn was. You're supposed to be buying the company for the product they have, and for their sales, not for their cash balance or any new marketing campaigns. You could wipe out all their debt, and MannKind still isn't making enough on Afrezza sales to pay their current bills.
The FDA panel is made up of highly educated people who can think for themselves. No fund manager who is short the stock is going to have any influence over that panel! It would be so obvious that he is doing that for only personal material profit, and not because he cares about diabetics.
It doesn't matter what Martin did. If it can be proven that he caused MannKind any damages by misrepresentations, then he can be sued for all the damages multiplied by 3.
Given that isn't happening, you're barking up the wrong tree.
As it is, Afrezza has been in the market for many months and it's barely selling, and I doubt if any of the potential users have ever heard of Martin Whatsisname.
So it's a bad investment. Get over it!
News 
Market Data 
Discover 
